MedTrace Logo

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1088

Last updated 2026-04-06

No results posted yet for this study

Summary

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).

The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Conditions

Interventions

DRUG

Zasocitinib

Zasocitinib over-encapsulated tablets.

DRUG

Active Comparator

Active comparator capsule.

DRUG

Placebo

Zasocitinib or active comparator matching placebo.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2027-05-18
Completion
2028-01-28
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • Chile
  • Croatia
  • Czechia
  • Estonia
  • Germany
  • Hungary
  • Israel
  • Italy
  • Latvia
  • Mexico
  • New Zealand
  • Poland
  • Portugal
  • Puerto Rico
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671483 on ClinicalTrials.gov